Loading...

SBFM SUNSHINE BIOPHARMA INC Capital Structure Changes 8-K Filing

SNSH

SBFM

SUNSHINE BIOPHARMA INC

(SBFM)

2026 8-K

Public Offering Explained

Financial Results Released

Warrant Solicitation Agreement

Reverse Stock Split

Management Change

Annual Meeting Results

Accounting Firm Change

Financial Statements

Securities Offering

Financial Results

Management Appointment

Annual Meeting Results

Financial Results

Management Changes

Financial Results

Exception Granted by Nasdaq

Financial Results Announcement

Appointment of Accountant

Accountant Change

Amendment to Articles of In...

Financial Results Announcement

Agreement and Reverse Stock...

Approval of Alternative Cas...

Public Offering

Buyback of Warrants

Management Appointments

Annual Meeting of Stockholders

Financial Results Announcement

Termination of Research Agr...

Amendment to Warrant Agent ...

Meeting Amendment

Notification of Non-Complia...

Earnings Reports

Private Placement

Financial Results Announcement

Amendment to Bylaws

Agreement with University o...

Compliance Regained

Research Agreement

External Links:

On March 6, 2026, Sunshine Biopharma Inc. entered into a three-month agreement with Aegis Capital Corp. to act as their warrant solicitation agent, with a fee of 10% on gross proceeds from warrant exercises during this period.

AI Assistant

SUNSHINE BIOPHARMA INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.